CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels
Aspergillosis Invasive, Fungal Infection
About this trial
This is an interventional treatment trial for Aspergillosis Invasive
Eligibility Criteria
Inclusion Criteria:
- All adult malignant hematology patients who are prescribed voriconazole.
Exclusion Criteria:
- Patients that have previously taken voriconazole within the last 2 weeks
Sites / Locations
- Toronto General Hospital
- Princess Margaret Cancer Care Centre
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
TDM Only
Genotyping + TDM
This is the standard of care trial arm. Patients receive voriconazole dosages according to the product monograph. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
After ascertaining CYP2C19 genetic status, the participants will be categorized as having either the ultra-rapid metabolizer (URM), extensive metabolizer (EM), heterozygous extensive metabolizer (HEM) or poor metabolizer (PM) phenotype. They will receive an experimental dosage regimen based on their phenotype. receive the following dosing regimen until TDM is conducted on day 4. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.